Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qian H Li

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Biometrical Journal. Biometrische Zeitschrift|February 17, 2009
Evaluating co-primary endpoints collectively in clinical trialsQian H Li
Journal of Biopharmaceutical Statistics|October 31, 2003
A decision rule for evaluating several independent clinical trials collectivelyQian H Li, Mohammad F Huque
Lifetime Data Analysis|February 5, 2005
Comparisons of test statistics arising from marginal analyses of multivariate survival dataQian H Li, Stephen W Lagakos
Journal of Biopharmaceutical Statistics|January 24, 2022
Conditional borrowing external data to establish a hybrid control arm in randomized clinical trialsHongfei Li, Ram Tiwari, Qian H Li
Therapeutic Innovation & Regulatory Science|May 24, 2021
Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity IssuesQian H Li, Qiqi Deng, Naitee Ting
Journal of Biopharmaceutical Statistics|October 24, 2024
Issues in cox proportional hazards model with unequal randomizationHongfei Li, Qian H Li, Chuan Tian, et al.
European Journal of Preventive Cardiology|July 23, 2021
Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studiesTahir Mahmood, Jessica Minnier, Matthew K Ito, et al.
Pharmaceutical Research|September 25, 2007
Bioequivalence approaches for highly variable drugs and drug productsSam H Haidar, Barbara Davit, Mei-Ling Chen, et al.
Circulation|January 13, 2021
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES TrialGregory G Schwartz, Philippe Gabriel Steg, Deepak L Bhatt, et al.
European Heart Journal|August 22, 2020
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trialJosé Tuñón, Philippe Gabriel Steg, Deepak L Bhatt, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Biometrical Journal. Biometrische Zeitschrift|February 17, 2009
Evaluating co-primary endpoints collectively in clinical trialsQian H Li
Journal of Biopharmaceutical Statistics|October 31, 2003
A decision rule for evaluating several independent clinical trials collectivelyQian H Li, Mohammad F Huque
Lifetime Data Analysis|February 5, 2005
Comparisons of test statistics arising from marginal analyses of multivariate survival dataQian H Li, Stephen W Lagakos
Journal of Biopharmaceutical Statistics|January 24, 2022
Conditional borrowing external data to establish a hybrid control arm in randomized clinical trialsHongfei Li, Ram Tiwari, Qian H Li
Therapeutic Innovation & Regulatory Science|May 24, 2021
Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity IssuesQian H Li, Qiqi Deng, Naitee Ting
Journal of Biopharmaceutical Statistics|October 24, 2024
Issues in cox proportional hazards model with unequal randomizationHongfei Li, Qian H Li, Chuan Tian, et al.
European Journal of Preventive Cardiology|July 23, 2021
Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studiesTahir Mahmood, Jessica Minnier, Matthew K Ito, et al.
Pharmaceutical Research|September 25, 2007
Bioequivalence approaches for highly variable drugs and drug productsSam H Haidar, Barbara Davit, Mei-Ling Chen, et al.
Circulation|January 13, 2021
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES TrialGregory G Schwartz, Philippe Gabriel Steg, Deepak L Bhatt, et al.
European Heart Journal|August 22, 2020
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trialJosé Tuñón, Philippe Gabriel Steg, Deepak L Bhatt, et al.
Pageof 2